Sanofi Stock: ScionxBio optimizes mRNA candidates - ad-hoc-news.de
Article excerpt
Highlighted: the sentence this signal was extracted from
On Wednesday, Sanofi entered into a global collaboration and licensing agreement with ScionxBio. The goal is to develop variants of selected mRNA candidates from Sanofi with extended exposure. The agreement thus opens up an additional development approach. It stands alongside new clinical results for Duvakitug and the expansion of insulin production, while quarterly figures are coming up on October 30. The collaboration relies on ScionxBio's TERA platform. ScionxBio will initially take over the optimization of the selected candidates up to and including validation in living organisms. Subsequently, Sanofi is to take over further development, manufacturing, and commercialization. Thus, the division of labor across the individual development phases is established. ScionxBio is responsible for early optimization, Sanofi for the subsequent steps. The agreement affects selected candidates and is not to be understood as a conversion of the entire mRNA portfolio. For investors, the developmental nature of the collaboration is particularly important. The targeted extended exposure describes the goal of the cooperation, not yet a proven clinical advantage. Furthermore, later responsibility for commercialization does not yet mean the approval of a product. Duvakitug is at a different stage of development. On Tuesday, Sanofi and Teva reported results from a Phase 2b extension study...
Keep reading with a free account
The rest of this article, and every signal for Sanofi, is in your free account.
